South Africa’s antitrust regulator has recommended that Roche (RHHBY) should be penalized for allegedly “excessive” pricing of its Herceptin breast cancer treatment, arguing it violates basic human rights by impeding access to a life-saving medicine.
More than 10,000 breast cancer patients — nearly half of the total number of newly diagnosed patients — were unable to obtain the medicine due to cost between 2011 and 2020 in the private and public health care sectors, according to the Competition Commission, which referred the matter to the Competition Tribunal for prosecution.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
